Abalone Bio
Abalone Bio is a preclinical-stage biotechnology company that develops functionally active antibody drugs targeting challenging disease targets, especially G-protein coupled receptors (GPCRs). Their proprietary Functional Antibody Selection Technology (FAST) platform enables rapid discovery of activating antibodies by biologically measuring hundreds of millions of antibodies for functional activity, not just binding. This large-scale activity dataset powers their machine learning models to design highly specific activating drugs that address diseases with fewer side effects. Abalone Bio has demonstrated success by discovering activators for two GPCRs, a rare achievement in the field, and is advancing internal therapeutic programs and partnerships focused on metabolic disease, inflammation, and cancer. Their business model includes both internal drug development and partnerships with pharmaceutical companies for discovery and co-development of antibody therapeutics.
Abalone Bio
Abalone Bio is a preclinical-stage biotechnology company that develops functionally active antibody drugs targeting challenging disease targets, especially G-protein coupled receptors (GPCRs). Their proprietary Functional Antibody Selection Technology (FAST) platform enables rapid discovery of activating antibodies by biologically measuring hundreds of millions of antibodies for functional activity, not just binding. This large-scale activity dataset powers their machine learning models to design highly specific activating drugs that address diseases with fewer side effects. Abalone Bio has demonstrated success by discovering activators for two GPCRs, a rare achievement in the field, and is advancing internal therapeutic programs and partnerships focused on metabolic disease, inflammation, and cancer. Their business model includes both internal drug development and partnerships with pharmaceutical companies for discovery and co-development of antibody therapeutics.